Ivabradine Teva (Ivabradine Hydrochloride)

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where heart‑rate reduction improves outcomes.

• Chronic stable angina: decreases the frequency of angina attacks by reducing myocardial oxygen demand.
• Heart failure with reduced ejection fraction (HFrEF): improves exercise capacity and may lower hospitalization risk.
• Inappropriate sinus tachycardia: provides rate control when beta‑blockers are unsuitable.

• Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows spontaneous depolarisation. By reducing the slope of phase 4 depolarisation, it lowers heart rate without affecting myocardial contractility or intracardiac conduction, thereby decreasing cardiac oxygen consumption while preserving systolic function.

Ivabradine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or light‑headedness.
• Fatigue or general weakness.
• Nausea or gastrointestinal discomfort.
• Bradycardia (heart rate <50 bpm).

Serious or Rare Side Effects

• Severe bradycardia requiring medical intervention.
• Atrial fibrillation or other significant arrhythmias.
• Symptomatic hypotension.
• High‑grade atrioventricular block.
• Persistent visual loss.
• Allergic reactions such as rash or angioedema.

Before initiating ivabradine, clinicians should consider several safety aspects.

• Cardiac monitoring: obtain baseline heart‑rate and ECG to ensure rate >60 bpm.
• Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin without careful monitoring.
• Severe hepatic impairment: use with caution as metabolism may be reduced.
• Pregnancy: avoid unless the potential benefit justifies the risk to the fetus.
• Renal impairment: assess renal function; dose adjustment may be needed.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase ivabradine plasma concentrations.
• Other bradycardic agents (e.g., beta‑blockers, digoxin): risk of severe bradycardia.
• QT‑prolonging drugs (e.g., certain antiarrhythmics): heightened arrhythmia risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine effectiveness.
• Calcium‑channel blockers verapamil or diltiazem: can raise ivabradine levels.
• Antacids containing aluminium or magnesium: may decrease oral absorption of ivabradine.